Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.97 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.97 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimetazidine SCHEMBL230374 | 1.00 | CHRM2 (1.00) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL11846840 | 1.00 | CHRM2 (1.00) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL3896420 | 0.98 | CHRM2 (0.97) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL29605009 | 0.98 | APOBEC3A (1.00) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL580378 | 0.98 | APOBEC3A (1.00) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL15302482 | 0.98 | CHRM2 (0.97) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL2901538 | 0.98 | APOBEC3A (1.00) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL348591 | 0.98 | APOBEC3A (1.00) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL29677959 | 0.98 | APOBEC3A (1.00) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 | |
| Trimetazidine SCHEMBL12485382 | 0.97 | CHRM2 (0.94) | CHRM2OPRK1CYP1A2SLC6A4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12156723-B2 | Energy conversion monitoring devices and methods | REVEAL BIOSENSORS, INC. (US) | 2024-12-03 | — | — | US | claimed |
| US-20230277068-A1 | SYSTEMS AND METHODS FOR CLASSIFYING CRITICAL HEART DEFECTS | UNIV CALIFORNIA (US) | 2023-09-07 | — | — | US | claimed |
| CN-114736215-B | Tetrahydrothienopyridine deuterated derivative and preparation method and pharmaceutical application thereof | 中荣凯特（北京）生物科技有限公司 | 2023-04-11 | — | — | CN | claimed |
| US-20230009171-A1 | ENERGY CONVERSION MONITORING DEVICES AND METHODS | REVEAL BIOSENSORS, INC. (US) | 2023-01-12 | — | — | US | claimed |
| US-20220361774-A1 | SYSTEMS AND METHODS FOR PERFORMING TRANS-ABDOMINAL FETAL OXIMETRY OR PULSE-OXIMETRY | RAYDIANT OXIMETRY, INC. | 2022-11-17 | — | — | US | claimed |
| US-11426093-B2 | Energy conversion monitoring devices, systems, and methods | REVEAL BIOSENSORS, INC. (US) | 2022-08-30 | — | — | US | claimed |
| CN-114736215-A | Tetrahydrothienopyridine deuterated derivative and preparation method and pharmaceutical application thereof | 中荣凯特（北京）生物科技有限公司 | 2022-07-12 | — | — | CN | claimed |
| EP-4003168-A1 | SYSTEMS AND METHODS FOR PERFORMING TRANS-ABDOMINAL FETAL OXIMETRY OR PULSE OXIMETRY | Raydiant Oximetry, Inc. (US) | 2022-06-01 | — | — | EP | claimed |
| US-20260108190-A1 | SYSTEMS, DEVICES, AND METHODS FOR PERFORMING TRANSABDOMINAL FETAL OXIMETRY AND/OR TRANSABDOMINAL FETAL PULSE OXIMETRY USING TWO TYPES OF OPTICAL MEASUREMENTS MODALITIES | RAYDIANT OXIMETRY INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4601538-A1 | SYSTEMS, DEVICES, AND METHODS FOR PERFORMING TRANSABDOMINAL FETAL OXIMETRY AND/OR TRANSABDOMINAL FETAL PULSE OXIMETRY USING TWO TYPES OF OPTICAL MEASUREMENTS MODALITIES | Raydiant Oximetry, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250242099-A1 | VASCULAR VALVES AND SERVOVALVES - AND PROSTHETIC DISORDER RESPONSE SYSTEMS | GOLDSMITH DAVID S (US) | 2025-07-31 | — | — | US | disclosed |
| CN-119775228-A | Simple and convenient method for preparing trimetazidine | 北京化工大学 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025043008-A1 | BIOMETRIC SIGNAL MANAGEMENT DEVICES AND METHODS | REVEAL BIOSENSORS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-12156723-B2 | Energy conversion monitoring devices and methods | REVEAL BIOSENSORS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-110623934-B | Trimetazidine hydrochloride sustained release tablet and preparation method thereof | 杭州百诚医药科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-110713471-B | Synthetic method of trimetazidine hydrochloride | 北京福元医药股份有限公司沧州分公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3976103-A1 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | Imbria Pharmaceuticals, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114213360-A | Preparation method of trimetazidine | 五峰赤诚生物科技股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3946172-A1 | RADIALLY SELF-EXPANDING STENTS | Edwards Lifesciences Corporation (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031254-A1 | AUTOMATED CONDITION SCREENING AND DETECTION | MASIMO CORPORATION | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108190-A1 | SYSTEMS, DEVICES, AND METHODS FOR PERFORMING TRANSABDOMINAL FETAL OXIMETRY AND/OR TRANSABDOMINAL FETAL PULSE OXIMETRY USING TWO TYPES OF OPTICAL MEASUREMENTS MODALITIES | ALPP, PGF, OXTR | CHRM2 1094/4885OPRK1 218/4885CYP1A2 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.